先前感染人地方性冠状病毒不会影响对SARS-CoV-2蛋白疫苗的体液免疫反应。
Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines.
作者信息
de Bruyn Guy, Adhikarla Haritha, Brackett Caroline K, Jia Yichen, Lakshmanane Premkumar, Mudrak Sarah V, Sawant Sheetal, Zhang Donghui, Chicz Roman M, Sridhar Saranya, Tomaras Georgia D, Seaton Kelly E
机构信息
Sanofi Vaccines Research & Development, Swiftwater, PA, USA.
Department of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University, Durham, NC, USA.
出版信息
NPJ Vaccines. 2025 Jul 13;10(1):153. doi: 10.1038/s41541-025-01203-z.
We included measurement of pre-existing immunity to human endemic coronaviruses (HCoV) in a Phase I/II study of SARS-CoV-2 spike protein vaccine candidates. A Binding Antibody Multiplex Assay measured HCoV-specific IgG to the receptor binding domain or full-length spike of human coronaviruses HKU1, 229E, NL63, and OC43. We found no evidence for the impact of HCoV antibodies on neutralizing and binding antibody responses to the candidate SARS-CoV-2 vaccines.
在一项针对新型冠状病毒 2 型（SARS-CoV-2）刺突蛋白候选疫苗的 I/II 期研究中，我们纳入了对人类地方性冠状病毒（HCoV）的既往免疫力的测量。一种结合抗体多重检测法测量了针对人类冠状病毒 HKU1、229E、NL63 和 OC43 的受体结合域或全长刺突的 HCoV 特异性 IgG。我们没有发现证据表明 HCoV 抗体对候选 SARS-CoV-2 疫苗的中和及结合抗体反应有影响。
Zotero 插件